French expenditure on reimbursable devices continues double-digit rise
This article was originally published in Clinica
The amount reimbursed by the French social security for medical products generally intended for direct use by individual patients in 2001 was E2,989bn ($2,800bn) compared with was some E2.7bn in 2000, an increase of 13%. This is an improvement compared with the average rate of some 15% over between 1998 and 2000, but is still much higher than the increase in the overall healthcare expenditure budget, which was set at 3.5% for 2001 and means that it will undoubtedly be targeted for cuts by the new government.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.